A patent update on cannabinoid receptor 1 antagonists (2015-2018)

References

• Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462.
   PubMed Web of Science ®Google Scholar
• Reggio PH. Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. Curr Med Chem. 2010;17(14):1468–1486.
   PubMed Web of Science ®Google Scholar
• Mouslech Z, Valla V. Endocannabinoid system: an overview of its potential in current medical practice. Neuro Endocrinol Lett. 2009;30(2):153–179.
   PubMed Web of Science ®Google Scholar
• Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease–successes and failures. FEBS J. 2013;280(9):1918–1943.
   PubMed Web of Science ®Google Scholar
• Picone RP, Kendall DA. Minireview: from the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation. Mol Endocrinol (Baltimore, Md). 2015;29(6):801–813.
   PubMed Web of Science ®Google Scholar
• Lu Y, Anderson HD. Cannabinoid signaling in health and disease. Can J Physiol Pharmacol. 2017;95(4):311–327.
   PubMed Web of Science ®Google Scholar
• Maccarrone M, Bab I, Biro T, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015;36(5):277–296.
   PubMed Web of Science ®Google Scholar
• Janero DR, Makriyannis A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs. 2009;14(1):43–65.
   PubMed Web of Science ®Google Scholar
• Kunos G, Tam J. The case for peripheral CB(1) receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol. 2011;163(7):1423–1431.
   PubMed Web of Science ®Google Scholar
• Chen W, Shui F, Liu C, et al. Novel peripherally restricted cannabinoid 1 receptor selective Antagonist TXX-522 with prominent weight-loss efficacy in diet induced obese mice. Front Pharmacol. 2017;8:707.
   PubMed Web of Science ®Google Scholar
• Ma H, Zhang G, Mou C, et al. Peripheral CB1 receptor neutral Antagonist, AM6545, ameliorates hypometabolic obesity and improves adipokine secretion in monosodium glutamate induced obese mice. Front Pharmacol. 2018;9:156.
   PubMed Web of Science ®Google Scholar
• Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370:1706–1713.
   PubMed Web of Science ®Google Scholar
• Chorvat RJ. Peripherally restricted CB1 receptor blockers. Bioorg Med Chem Lett. 2013;23(17):4751–4760.
   PubMed Web of Science ®Google Scholar
• Sharma MK, Murumkar PR, Kanhed AM, et al. Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists. Eur J Med Chem. 2014;79:298–339.
   PubMed Web of Science ®Google Scholar
• Silvestri C, Di Marzo V. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Expert Opin Investig Drugs. 2012;21(9):1309–1322.
   PubMed Web of Science ®Google Scholar
• Klumpers LE, Fridberg M, Kam ML, et al. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. Br J Clin Pharmacol. 2013;76(6):846–857.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Li JX, Thomas BF, et al. Allosteric modulation:an Alternate approach targeting the cannabinoid CB1 receptor. Med Res Rev. 2017;37(3):441–474.
   PubMed Web of Science ®Google Scholar
• Sharma MK, Murumkar PR, Barmade MA, et al. A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015;25(10):1093–1116.
   PubMed Web of Science ®Google Scholar
• Beijing Institute of Pharmacology & Toxicology, Academy of Military Medical Sciences. 4-Methyl-1H-diaryl pyrazole derivatives and uses as drugs thereof. 2016. p. WO2016184310.
   Google Scholar
• Hanmi Pharmaceutical. 4,5-Dihydro-1H-pyrazole-3-carboximidamide derivatives containing sulfur groups, method for preparing same, and pharmaceutical composition comprising same. 2015. WO2015152550.
   Google Scholar
• Hanmi pipeline. Hanmi Pharmaceutical; 2019 [cited 2019 Feb 22]. Available from: http://www.hanmipharm.com/ehanmi/handler/Rnd-Pipeline
   Google Scholar
• Janssen Pharmaceutica NV. Quinoline derivatives useful as cb-1 inverse agonists. 2015. WO2015130444.
   Google Scholar
• Janssen Pharmaceutica NV. Quinoline derivatives useful as cb-1 inverse agonists. 2015. WO2015130445.
   Google Scholar
• Janssen Pharmaceutica NV. Quinoline derivatives useful as CB-1 inverse agonists. 2016. US9266835.
   Google Scholar
• Janssen Pharmaceutica NV. Quinoline derivatives useful as CB-1 inverse agonists. 2016. US9464055.
   Google Scholar
• Janssen Pharmaceutica NV. Cinnoline derivatives useful as cb-1 receptor inverse agonists. 2016. WO2016115013.
   Google Scholar
• Janssen Pharmaceutica NV. Quinazoline derivatives useful as cb-1 inverse agonists. 2016. WO2016040081.
   Google Scholar
• Janssen Pharmaceutica NV. Cinnoline derivatives useful as CB-1 receptor inverse agonists. 2017. US9732061.
   Google Scholar
• Janssen Pharmaceutica NV. Indazole derivatives useful as CB-1 inverse agonists. 2017. US9682940.
   Google Scholar
• Janssen Pharmaceutica NV. Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists. 2017. US9815790.
   Google Scholar
• Janssen Pharmaceutica NV. Quinazoline derivatives useful as CB-1 inverse agonists. 2017. US9682955.
   Google Scholar
• Janssen Pharmaceutica NV. Indazole derivatives useful as cb-1 inverse agonists. 2017. WO2017034872.
   Google Scholar
• Janssen Pharmaceutica NV. Benzimidazole derivatives useful as cb-1 inverse agonists. 2017. WO2017035114.
   Google Scholar
• Janssen Pharmaceutica NV. Chemically modified quinoline and quinolone derivatives useful as cb-1 inverse agonists. 2017. WO2017034877.
   Google Scholar
• Janssen Pharmaceutica NV. Benzimidazole derivatives useful as CB-1 inverse agonists. 2018. US10118900.
   Google Scholar
• Zhang Y-M, Greco MN, Macielag MJ, et al. 6-Benzhydryl-4-amino-quinolin-2-ones as potent cannabinoid type 1 (CB1) receptor inverse agonists and chemical modifications for peripheral selectivity. J Med Chem. 2018;61(22):10276–10298.
   PubMed Web of Science ®Google Scholar
• Selected pharmaceuticals in late stage U.S. and E.U. development or registration. Janssen Pharmaceutical Companies of Johnson & Johnson; 2019 [cited 2019 Feb 22]. Available from: https://jnj-content-lab.brightspotcdn.com/cd/89/89043e9145439087cd8986134485/jnj-pipeline-4q2018.pdf
   Google Scholar
• Jenrin Discovery Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes. 2018. US9987253.
   Google Scholar
• Jenrin Discovery Inc. Cannabinoid receptor antagonists/inverse agonists. 2016. p. EP2877173.
   Google Scholar
• Jenrin Discovery Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes. 2016. US9517228.
   Google Scholar
• Chorvat RJ, Berbaum J, Seriacki K, et al. JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. Bioorg Med Chem Lett. 2012;22(19):6173–6180.
   PubMed Web of Science ®Google Scholar
• Jenrin Discovery’s IND application for its peripherally restricted cannabinoid-1 receptor inverse agonist NASH compound was cleared by the FDA to begin phase 1 clinical trials. Business Wire; 2017 December 14 [cited 2019 Feb 20]. Available from: https://www.businesswire.com/news/home/20171214005128/en/Jenrin-Discovery%E2%80%99s-IND-Application-Peripherally-Restricted-Cannabinoid-1
   Google Scholar
• Corbus pharmaceuticals expands target indications by adding more than 600 compounds focused on the endocannabinoid system from Jenrin Discovery; Includes CRB-4001 with planned NIH-supported phase 2 study. Corbus Pharmaceuticals Holdings, Inc; 2018 September 20 [cited 2019 Feb 20]. Available from: https://www.corbuspharma.com/news/press-releases/detail/282/corbus-pharmaceuticals-expands-target-indications-by-adding
   Google Scholar
• Research Triangle Institute. Peripherally restricted diphenyl purine derivatives. 2016. US9458160.
   Google Scholar
• Research Triangle Institute. Diaryl purine derivatives with improved bioavailability. 2017. US2017067602.
   Google Scholar
• Research Triangle Institute. Diaryl purine derivatives with improved bioavailability. 2018. WO2018119076.
   Google Scholar
• Universite de Nantes, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Bourgogne. 1,4-Di-(4-methylthiophenyl)-3-phtaloylazetidine-2-one and the derivatives thereof. 2018. EP3353165.
   Google Scholar
• Universite de Nantes, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Bourgogne. 1,4-Di-(4-methylthiophenyl)-3-phtaloylazetidine-2-one and the derivatives thereof. 2018. US20180265498.
   Google Scholar
• Universite de Nantes, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Bourgogne. 1,4-Di-(4-methylthiophenyl)-3-phtaloylazetidine-2-one and the derivatives thereof. 2017. WO2017050990.
   Google Scholar
• US Department of Health and Human Services. Cannabinoid receptor mediating compounds. 2015. EP2919779.
   Google Scholar
• US Department of Health and Human Services. Cannabinoid receptor mediating compounds. 2015. WO2014078309.
   Google Scholar
• US Department of Health and Human Services. Pyrazole derivatives and their use as cannabinoid receptor mediators. 2016. WO2015172059.
   Google Scholar
• US Department of Health and Human Services. Cannabinoid receptor mediating compounds. 2016. US20160257654.
   Google Scholar
• US Department of Health and Human Services. Cannabinoid receptor mediating compounds. 2017. WO2016196646.
   Google Scholar
• US Department of Health and Human Services. Pyrazole derivatives and their use as cannabinoid receptor mediators. 2017. EP3140288.
   Google Scholar
• US Department of Health and Human Services. Cannabinoid receptor mediating compounds. 2018. US20180273485.
   Google Scholar
• US Department of Health and Human Services. Pyrazole derivatives and their use as cannabinoid receptor mediators. 2018. US20180179163.
   Google Scholar
• US Department of Health and Human Services. Cannabinoid receptor mediating compounds. 2018. US20180022705.
   Google Scholar
• US Department of Health and Human Services. Cannabinoid receptor mediating compounds. 2018. EP3303325.
   Google Scholar
• Northeastern University. Allosteric modulators of the cannabinoid 1 receptor. 2018. US9926275.
   Google Scholar
• Northeastern University. Allosteric modulators of the cannibinoid 1 receptor. 2015. WO2015027160.
   Google Scholar
• Research Triangle Institute. Diaryl ureas as CB1 allosteric modulators. 2018. US2018031977.
   Google Scholar
• Research Triangle Institute. Diaryl ureas as cb1 allosteric modulators. 2018. WO2018209030.
   Google Scholar
• Universite de Bordeaux, Institut National de la Sante et de la Recherche Medicale. Antagonists of CB1 receptor. 2018. US10040816.
   Google Scholar
• University of Arkansas, University of Kansas. Use of the aminoalkylindole JWH-073-M4 and related compounds as neutral CB1 receptor antagonists for the treatment of alcoholism, drug abuse, obesity, and obesity-related diseases. 2016. US9416103.
   Google Scholar
• University of North Carolina at Greensboro. Beta-arrestin-biased cannabinoid CB1 receptor agonists and methods for making and using them. 2018. US10118914.
   Google Scholar
• University of North Carolina at Greensboro. Beta-arrestin-biased cannabinoid cb1 receptor agonists and methods for making and using the. 2015. WO2015195486.
   Google Scholar
• Amgen Inc. CB-1 receptor antigen-binding proteins and uses thereof. 2016. US20160145333.
   Google Scholar
• Amgen Inc. Cb1 receptor antigen-binding proteins and uses thereof. 2018. EP3013860.
   Google Scholar
• Amgen pipeline. Amgen; 2019. Available from: https://www.amgenpipeline.com/~/media/amgen/full/www-amgenpipeline-com/charts/amgen-pipeline-chart.ashx
   Google Scholar
• Bird Rock Bio Inc. Antibodies that bind human cannabinoid 1 (CB1) receptor. 2018. US20180282406.
   Google Scholar
• Bird Rock Bio Inc. Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor. 2017. US20170210797.
   Google Scholar
• Bird rock bio completes single ascending dose human clinical trial for RYI-018; generates safety, tolerability, and pharmacokinetics data; prepares to initiate study in non-alcoholic fatty liver disease patients. Bird Rock Bio; 2017 June 5 [cited 20 Feb 2019]. Available from: http://www.birdrockbio.com/2017/06/05/bird-rock-bio-completes-single-ascending-dose-human-clinical-trial-for-namacizumab-generates-safety-tolerability-and-pharmacokinetics-data-prepares-to-initiate-study-in-non-alcoholic-fatty-liver-d/
   Google Scholar
• Icahn School of Medicine at Mount Sinai. Antibodies which bind type I cannabinoid receptor/angiotensin II receptor heteromers and methods of use. 2018. US9855290.
   Google Scholar
• Icahn School of Medicine at Mount Sinai. Antibodies which bind type i cannabinoid receptor/angiotensis ii receptor heteromers. 2018. US20180250322.
   Google Scholar
• Northeastern University. Cannabinergic nitrate esters and related analogs. 2017. US9580400.
   Google Scholar
• Northeastern University. Cannabinergic nitrate esters and related analogs. 2017. US20170210728.
   Google Scholar
• Fundacion del Hospital Nacional de Paraplejicos Para la Investigacion y la Integracion. Use of CB1 antagonists and/or inverse agonists for the preparation of drugs that increase motor neuron excitability. 2017. . US9592237.
   Google Scholar
• Universitat Pompeu Fabra. Antagonists of the cannabinoid receptor CB1 for use in the treatment of diseases associated with neuronal dendritic abnormalities. 2017. US9662320.
   Google Scholar
• Universitat Pompeu Fabra. Antagonists of the cannabionoid receptor cb1 for use in the treatment of diseases associated with neuronal dendritic abnormalities. 2016. EP2976074.
   Google Scholar
• The Board Of Regents Of The University Of Texas System. Methods of treating synthetic cannabinoid toxicity or overdose with rimonabant. 2018. WO2018204689.
   Google Scholar
• Shao Z, Yin J, Chapman K, et al. High-resolution crystal structure of the human CB1 cannabinoid receptor. Nature. 2016November16;(540):602. online.
   PubMedGoogle Scholar
• Hua T, Vemuri K, Pu M, et al. Crystal structure of the human cannabinoid receptor CB1. Cell. 2016 Oct 20;167(3):750–62.e14.
   PubMed Web of Science ®Google Scholar
• Hua T, Vemuri K, Nikas SP, et al. Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature. 2017 Jul 27;547(7664):468–471.
   PubMed Web of Science ®Google Scholar